Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin
Shin Yeu Ong, Lu Chen, Jomel Meeko Manzano, Reid W. Merryman et autres
Frontline therapy for classic Hodgkin Lymphoma (cHL) incorporating brentuximab vedotin (BV) improves outcomes compared with traditional chemotherapy, but up to 20% of patients relapse and need salvage treatment. Prior retrospective studies examining salvage therapies are mostly limited to patients who received chemotherapy-based …
sg, us (code pays fourni par la source)
0 citations
Blood Cancer Journal